BMRA news & sentiment — BIOMERICA INC

APR 14·Stock TitanHigh

Up to 5 million Canadians have IBS; Biomerica brings inFoods north

Biomerica (Nasdaq: BMRA) has launched its inFoods® IBS platform in Canada through partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs. This marks Biomerica's first commercial entry into Canada, aiming to address the estimated 18% prevalence of IBS (up to 5 million Canadians) with a clinically validated, non-pharmaceutical, diagnostic-guided therapy. The initiative seeks to fill a significant unmet need in a market largely focused on pharmaceutical symptom management.

MAR 22·Intellectia AI

BMRA PE Ratio & Valuation, Is BMRA Overvalued

Biomerica Inc (BMRA) is currently considered undervalued based on its forward P/S ratio of 0.28, significantly lower than its five-year average of 12.51. The fair price for BMRA is estimated between 3097.35 to 3125.16, making its current price of 2.19 USD appear to be undervalued by 99.93%. Despite a P/S ratio that is -99.98% above the industry average, its revenue growth of -26.04% suggests this premium may be unsustainable.

NOV 25·Benzinga

Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS - Biomerica ( NASDAQ:BMRA )

IRVINE, Calif., Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Biomerica, Inc. ( NASDAQ:BMRA ) , a global provider of advanced medical diagnostic solutions, is proud to announce that its inFoods® IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a ...

$BMRA

Up to 5 million Canadians have IBS; Biomerica brings inFoods north

BMRA PE Ratio & Valuation, Is BMRA Overvalued

Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS - Biomerica ( NASDAQ:BMRA )

News on $BMRA